Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (NCT04794699)
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Who can join: Review the eligibility criteria below.
Location: Honor Health Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Honor Health Research Institute — Scottsdale, Arizona
- Rockefeller Cancer Institute — Little Rock, Arkansas
- City of Hope — Duarte, California
- Orlando Health Cancer Institute — Orlando, Florida
- Indiana University Health Hospital — Indianapolis, Indiana
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Columbia University Medical Center - Herbert Irving Pavilion — New York, New York
- Weill Cornell Medical College — New York, New York
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- LifeSpan - Brown University — Providence, Rhode Island
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson — Houston, Texas
- Next Oncology — San Antonio, Texas
- Swedish Cancer Institute — Seattle, Washington
- The Kinghorn Cancer Centre, St Vincent's Health Network Sydney — Darlinghurst, New South Wales
- Southern Oncology Clinical Research Unit — Bedford Park, South Australia
- Institut Bergonie — Bordeaux, Bordeaux Cedex
- Institut Claudius Regaud - IUCT-Oncopole — Toulouse, Cedex 9
- Hôpital Timone — Marseille, Marseille
- Centre Georges Francois LeClerc — Dijon,
- Centre Eugène Marquis — Rennes,
- Gustave Roussy — Villejuif,
- Universitaetsklinikum Hamburg-Eppendorf (UKE) — Hamburg,
- National Cancer Center — Goyang-si, Gyeonggi-do
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.